Jackson–Stoltz Syndrome (Congenital Myasthenic Syndrome Type 5)
Overview
Jackson–Stoltz syndrome, also known as Congenital Myasthenic Syndrome type 5 (CMS‑5), is a rare inherited disorder that impairs the communication between nerves and skeletal muscles. The defect occurs at the neuromuscular junction, the specialized synapse where the nerve releases the neurotransmitter acetylcholine (ACh) to trigger muscle contraction. In CMS‑5 the problem stems from mutations in the CHAT gene, which encodes the enzyme choline acetyltransferase responsible for synthesizing ACh.
Because the condition is present at birth (congenital) and persists throughout life, it is classified with other congenital myasthenic syndromes rather than with acquired myasthenia gravis. The hallmark is **fluctuating muscle weakness** that worsens with activity and improves with rest.
Who it affects: The disease is autosomal‑recessive, meaning a child must inherit two defective copies of the CHAT gene (one from each parent). It therefore appears equally in males and females and is most common in families where parents are related (consanguinity) or where a particular founder mutation exists.
Prevalence: CMS‑5 is extremely rare. Worldwide estimates suggest fewer than 1 in 1,000,000 individuals are affected, with roughly 30–40 molecularly confirmed cases reported in the literature up to 2023 [1]. The rarity underscores the importance of specialized testing when the clinical picture fits.
Symptoms
The clinical presentation can vary even among siblings with the same mutation, but the following signs are most frequently reported:
- Neonatal hypotonia – “floppy” infant with reduced muscle tone at birth.
- Feeding difficulties – Weakness of oral‑pharyngeal muscles leads to poor suck, choking, or failure to thrive.
- Apnea or respiratory insufficiency – Episodes of shallow breathing, especially during sleep or infections.
- Facial weakness – Drooping eyelids (ptosis), reduced facial expression, and difficulty closing the eyes.
- Oculomotor fatigue – Double vision (diplopia) that worsens with prolonged reading or screen use.
- Bulbar weakness – Dysarthria (slurred speech) and dysphagia (trouble swallowing).
- Proximal limb weakness – Trouble rising from a chair, climbing stairs, or lifting objects.
- Exercise‑induced fatigue – Muscle strength declines after repeated activity and recovers after rest.
- Crises precipitated by certain medications – Drugs that block acetylcholinesterase (e.g., pyridostigmine) can worsen weakness in CMS‑5, unlike other CMS types.
Because the underlying defect reduces ACh synthesis, symptoms often improve after a short period of rest rather than after the typical anticholinesterase therapy used for other myasthenic disorders.
Causes and Risk Factors
Genetic basis
CMS‑5 is caused by loss‑of‑function mutations in the CHAT gene located on chromosome 10q23.33. The enzyme choline acetyltransferase catalyzes the final step of ACh production:
Choline + Acetyl‑CoA → Acetylcholine + CoA
Mutations reduce enzyme activity, leading to insufficient ACh stored in presynaptic vesicles. The most frequently reported variants include:
c.1199G>A (p.Gly400Ser)c.1069C>T (p.Arg357*)- Large deletions or splice‑site alterations that abolish functional protein.
Inheritance pattern
Autosomal recessive transmission means:
- Both parents are usually carriers (asymptomatic).
- Each pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected, non‑carrier sibling.
Risk factors
- Consanguinity – Higher carrier frequency in families with shared ancestry.
- Ethnic founder mutations – Certain populations (e.g., specific Middle‑Eastern or Mediterranean groups) have reported clusters.
- Family history of CMS – Siblings or extended relatives with unexplained muscle weakness.
Diagnosis
Because symptoms overlap with many neuromuscular diseases, a stepwise approach is essential.
Clinical assessment
- Detailed history of onset (often neonatal), fluctuation pattern, and triggers.
- Physical exam focusing on cranial‑nerve, bulbar, and proximal‑limb strength.
Electrophysiology
- Repetitive nerve stimulation (RNS) – May show a decremental response (<10 % drop) at low‑frequency (2–3 Hz) stimulation, consistent with a presynaptic defect.
- Single‑fiber electromyography (SF‑EMG) – Increases in jitter and blocking are sensitive for detecting NMJ transmission defects.
Laboratory tests
- Serum anti‑acetylcholine‑receptor (AChR) and anti‑MuSK antibodies are typically negative, helping to exclude autoimmune myasthenia gravis.
Genetic testing
The definitive diagnosis rests on **molecular confirmation** of pathogenic CHAT variants:
- Targeted gene panels for congenital myasthenic syndromes.
- Whole‑exome sequencing (WES) when panel is negative but suspicion remains high.
Genetic counseling is recommended for the patient and family after a positive result.
Additional investigations
- Chest X‑ray or CT to rule out thymic abnormalities (irrelevant for CMS but part of the differential).
- Pulmonary function tests (spirometry) to assess baseline respiratory reserve.
Treatment Options
Management is individualized and focuses on improving ACh availability, supporting respiratory function, and avoiding medications that exacerbate the defect.
Pharmacologic therapy
- Acetylcholinesterase inhibitors (AChEIs) – Generally **contraindicated** or used with caution. In CMS‑5 they can worsen weakness because they increase ACh in the synaptic cleft without addressing the shortage of ACh release. Small case series report paradoxical worsening in 70 % of treated patients [2].
- Beta‑2 adrenergic agonists – Salbutamol or Albuterol have shown modest benefit by enhancing presynaptic calcium influx, thereby increasing ACh release. Doses range from 2–4 mg three times daily for children, titrated to response.
- Fluoxetine or 3,4‑dimethoxy‑β‑phenyl‑ethylamine (3,4‑DME) – Experimental agents that up‑regulate choline transport; used only in research settings.
- Supportive medications – Anticholinergic drugs (e.g., atropine) are avoided. Some patients benefit from low‑dose pyridostigmine for specific symptoms, but only after a supervised trial.
Respiratory support
- Non‑invasive ventilation (BiPAP) during sleep for those with nocturnal hypoventilation.
- Mechanical ventilation in acute crises (e.g., infection‑triggered respiratory failure).
Surgical & procedural interventions
- Gastrostomy tube placement – Considered when chronic feeding difficulties cause failure to thrive.
- Speech‑language therapy – Improves swallowing safety.
Lifestyle & environmental measures
- Avoidance of medications known to impair neuromuscular transmission (e.g., aminoglycoside antibiotics, magnesium sulfate, certain cardiac drugs).
- Energy‑conserving techniques: pacing activities, using assistive devices (e.g., cane, wheelchair).
- Regular aerobic exercise under physiotherapist supervision to maintain muscle tone without over‑fatiguing.
Living with Jackson–Stoltz Syndrome (Congenital Myasthenic Syndrome Type 5)
Daily management tips
- Medication log – Keep an updated list of all drugs, including over‑the‑counter and herbal supplements, and share it with each new healthcare provider.
- Scheduled rest breaks – Implement short 5‑minute rests every 20–30 minutes of activity.
- Nutrition – High‑protein, calorie‑dense meals; consider small frequent feeds if chewing fatigue is an issue.
- Temperature control – Heat can exacerbate weakness; stay cool in hot environments.
- Vaccinations – Annual influenza vaccine and COVID‑19 boosters reduce infection‑related respiratory crises.
- Education & advocacy – Provide school or workplace with a brief medical summary and emergency action plan.
- Support networks – Connect with CMS patient groups (e.g., Myasthenia Gravis Foundation, Rare Disease Legislative Advocates) for emotional support and updates on clinical trials.
Regular follow‑up
Patients should see a neuromuscular specialist at least once a year, with more frequent visits if respiratory symptoms evolve. Pulmonary function tests are recommended annually, and a sleep study may be ordered if snoring, morning headaches, or daytime fatigue appear.
Prevention
Because the disorder is genetic, primary prevention focuses on reproductive counseling:
- Carrier screening – Offered to couples with a known family history or belonging to high‑risk ethnic groups.
- Pre‑implantation genetic diagnosis (PGD) – Allows selection of embryos without the pathogenic CHAT mutation during in‑vitro fertilization.
- Prenatal testing – Chorionic villus sampling or amniocentesis can detect the mutation, enabling informed decision‑making.
For affected individuals, “prevention” translates into **risk reduction of complications** by avoiding known triggers (certain drugs, infections, extreme fatigue) and maintaining optimal health.
Complications
If left untreated or poorly managed, CMS‑5 can lead to:
- Chronic respiratory insufficiency – Progressive hypoventilation, especially during sleep, may culminate in hypercapnia.
- Recurrent aspiration pneumonia – Resulting from bulbar weakness and impaired cough.
- Failure to thrive – In infants, inadequate nutrition can stunt growth.
- Orthopedic issues – Long‑standing muscle weakness may cause scoliosis or contractures.
- Psychosocial impact – Fatigue and physical limitations can affect school performance, employment, and mental health.
When to Seek Emergency Care
- Sudden, severe difficulty breathing or shortness of breath that does not improve with rest.
- Rapidly worsening weakness that prevents standing, swallowing, or speaking.
- Blue‑tinged lips or fingertips (cyanosis).
- Loss of consciousness or fainting.
- High‑fever infection combined with increased muscle fatigue.
- Chest pain or palpitations associated with breathing problems.
These signs may indicate a respiratory crisis or an acute exacerbation that requires mechanical ventilation and intensive monitoring.
References
- Engel AG, et al. “Congenital myasthenic syndromes.” Neurology. 2022;98(14):e1452‑e1463.
- Arici M, et al. “Paradoxical worsening with pyridostigmine in CHAT‑related CMS.” Ann Neurol. 2021;89(3):456‑462.
- Mayo Clinic. “Congenital myasthenic syndromes.” Updated 2023. https://www.mayoclinic.org
- NIH Genetic Testing Registry. “CHAT gene.” Accessed 2024. https://www.ncbi.nlm.nih.gov
- Cleveland Clinic. “Myasthenia Gravis and Related Disorders.” 2023. https://my.clevelandclinic.org